Pulmotect Announces Appointment of Néstor Molfino, MD as President and Chief Executive Officer

Néstor Molfino
Dr. Néstor Molfino holds a medical degree from Universidad Nacional de Rosario in Argentina, completing an internship and residency in internal medicine and respiratory medicine.

Pulmotect, Inc., a clinical-stage biotechnology company developing an inhaled pathogen-agnostic, host-directed immunomodulator (PUL-042), announces that Respiratory Medicine specialist Néstor A. Molfino, MD, has joined the company as President and Chief Executive Officer.

“Dr. Molfino brings to Pulmotect an impressive background of accomplishment in respiratory drug development,” said Leo E. Linbeck III, Chairman of the Board of Pulmotect. “We are pleased that the promise of Pulmotect’s novel approach to infection prevention and treatment were able to bring Néstor to Houston from San Francisco, and we look forward to continued progress at the company.”

Immediately prior to his position with Pulmotect, Dr. Molfino was an independent consultant to biopharmaceutical companies, clinical research organizations (CROs), investors and patient organizations in planning, designing and execution of drug development and commercial strategies. From 2012 to 2015, Dr. Molfino was the Chief Medical Officer at South San Francisco-based KaloBios Pharmaceuticals, Inc. Prior to that, he was Vice President, Clinical Development and Respiratory Therapeutic Area Head at MedImmune, Inc. (now part of AstraZeneca Biologics). Dr. Molfino started his career in the biopharmaceutical industry in 1994. Additionally, for the past 16 years Dr. Molfino has served as a pulmonary and allergy consultant to Fermin Salaberry, a non-profit public community hospital assisting underserved populations in Argentina.

Dr. Molfino received a Master’s Degree in Molecular and Cell Biology from the University of Toronto. He holds a Medical Degree from Universidad Nacional de Rosario in Argentina, completing an internship and residency in Internal Medicine and Respiratory Medicine, after which he completed a post-doctoral fellowship in lung physiology at the University of Toronto, where he was appointed assistant professor in 2004. In 2006, he was appointed Adjunct Professor at McGill University in Montreal, Canada.

“We will aim at reducing morbidity and ultimately mortality in patients suffering from immune suppression, chronic respiratory conditions and even in the general population in the case of pandemias from new emerging threats”

“I am excited to join Pulmotect, a company that has a disruptive therapy to reduce the impact of respiratory infections in different patient populations. We will aim at reducing morbidity and ultimately mortality in patients suffering from immune suppression, chronic respiratory conditions and even in the general population in the case of pandemias from new emerging threats,” said Dr. Molfino. “Pulmotect has solid science, and I am thrilled to be part of an exceptional team as it works toward the goal of benefiting broad populations.”

Dr. Brenton Scott, a founder of Pulmotect and formerly President, has moved into the role of COO and Director of Business Development and Government Affairs. “Dr. Scott has been instrumental in bringing the company from the bench side to completing two Phase I studies in healthy volunteers. He will continue to be an integral part of our strategy and execution,” said Dr. Molfino.


About Pulmotect, Inc.

Pulmotect is actively developing PUL-042 (a TLR 2, 6 and 9 agonist), a drug which has been the subject of two Phase I clinical trials, with a Phase Ib trial scheduled in the second quarter of 2017. Pulmotect’s technology is licensed from The Texas A&M University System and The University of Texas MD Anderson Cancer Center. Pulmotect partnered in 2008 with Fannin Innovation Studio to assist in the drug’s commercial development. Pulmotect is the recipient of multiple early stage investments and grants, as well as recognition and awards from the biotechnology community. The Company was awarded $7.1 million from the Cancer Prevention Institute of Texas (CPRIT). More information

About Fannin Innovation Studio

Houston-based Fannin Innovation Studio is an early-stage life sciences development group focused exclusively on commercializing medical technologies. Fannin partners with life science innovators to cofound startup companies and provides a pooled management team, funding, and administrative support. To further bridge the commercialization gap, Fannin’s internship, and fellowship programs provide aspiring entrepreneurs with hands-on development experience with its portfolio companies. More information.